BusinessCascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in EuropeBy Nasdaq OMXJul 11, 2017, 12:01 PM UTC
BusinessOncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121By Nasdaq OMXJul 7, 2017, 12:30 PM UTC
BusinessTaconic Biosciences and Pharmatest Services Ltd. Create First Human Immune System Model for Bone MetastasisBy Nasdaq OMXJul 5, 2017, 8:40 PM UTC
BusinessWhen a Unicorn Stands Behind Breast Cancer Research, Magic HappensBy Nasdaq OMXJun 20, 2017, 1:00 PM UTC
BusinessAmerican Airlines Donates $1 Million to Stand Up to CancerBy Nasdaq OMXJun 10, 2017, 10:00 PM UTC
BusinessCascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain MetastasesBy Nasdaq OMXJun 8, 2017, 12:01 PM UTC
BusinessBritish Breast Cancer Epidemic Correlates with Fertility and Induced Abortion, according to the Journal of American Physicians and SurgeonsBy Nasdaq OMXMar 22, 2017, 3:27 PM UTC
BusinessCascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support RegistrationBy Nasdaq OMXDec 7, 2016, 12:00 PM UTC
